A German collaboration seeks to treat the symptoms of hemophilia in patients suffering from the later. CEVEC and Biotest will join forces to produce and commercialize molecules using CEVEC’s expression platform.
Biotest develops immunoglobulins, coagulation factors and albumins, based on human blood plasma, used for diseases of the immune and hematopoietic system. This makes it an important partner to test CEVEC’s CAPGo expression system. The expression platform, in fact, produces recombinant complexly glycosylated molecules, such as coagulation factors and other plasma proteins.
The platform comprises a portfolio of glyco-optimized human cell lines that provide authentic human post-translational modifications. It has already been proven to not only enhance the activity and stability of several candidate proteins, but also enables easier scale-up in comparaison to adherent cell culture systems.
Under the terms of the license agreement, CEVEC will receive service fees for ongoing development support, upfront and milestone payments, as well as royalties on future product sales.